Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer.

Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, Ueno NT, Lim B.

Surg Clin North Am. 2018 Aug;98(4):787-800. doi: 10.1016/j.suc.2018.03.009. Epub 2018 May 24. Review.

PMID:
30005774
2.

American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation.

DeSnyder SM, Hunt KK, Dong W, Smith BD, Moran MS, Chavez-MacGregor M, Shen Y, Kuerer HM, Lucci A.

Ann Surg Oncol. 2018 Jul 9. doi: 10.1245/s10434-018-6580-9. [Epub ahead of print]

PMID:
29987598
3.

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT.

JAMA Oncol. 2018 Jun 7. doi: 10.1001/jamaoncol.2018.1436. [Epub ahead of print]

PMID:
29879283
4.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 May 30. doi: 10.1158/1078-0432.CCR-17-3649. [Epub ahead of print]

PMID:
29848573
5.

Circulating Tumor Cells in Stage IV Melanoma Patients.

Hall CS, Ross M, Bowman Bauldry JB, Upshaw J, Karhade MG, Royal R, Patel S, Lucci A.

J Am Coll Surg. 2018 Jul;227(1):116-124. doi: 10.1016/j.jamcollsurg.2018.04.026. Epub 2018 May 7.

PMID:
29746918
6.
7.

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA.

J Cancer. 2018 Apr 6;9(8):1437-1447. doi: 10.7150/jca.23969. eCollection 2018.

8.

Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.

Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT.

J Cancer. 2017 Oct 9;8(17):3607-3614. doi: 10.7150/jca.21200. eCollection 2017.

9.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
10.

A usable model of "decathlon winner" cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence.

Singh B, Sarli VN, Washburn LJ, Raythatha MR, Lucci A.

Oncotarget. 2018 Jan 25;9(13):11071-11082. doi: 10.18632/oncotarget.24322. eCollection 2018 Feb 16.

11.

Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.

van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A Jr, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM.

Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21.

PMID:
29465744
12.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
13.

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

Fayanju OM, Park KU, Lucci A.

Ann Surg Oncol. 2018 Feb;25(2):512-519. doi: 10.1245/s10434-017-6254-z. Epub 2017 Nov 20. Review.

14.

Best practices for multidisciplinary integration of a DCIS genomic assay into clinical practice.

Alvarado M, Lucci A, Manders J.

J Surg Oncol. 2017 Dec;116(8):1016-1020. doi: 10.1002/jso.24754. Epub 2017 Aug 22.

PMID:
28833159
15.

Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery.

Rosso KJ, Tadros AB, Weiss A, Warneke CL, DeSnyder S, Kuerer H, Ueno NT, Stecklein SR, Woodward WA, Lucci A.

Ann Surg Oncol. 2017 Oct;24(10):2981-2988. doi: 10.1245/s10434-017-5952-x. Epub 2017 Aug 1.

PMID:
28766220
16.

Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer.

DeSnyder SM, Mittendorf EA, Le-Petross C, Krishnamurthy S, Whitman GJ, Ueno NT, Woodward WA, Kuerer HM, Akay CL, Babiera GV, Yang W, Lucci A.

Clin Breast Cancer. 2018 Feb;18(1):e73-e77. doi: 10.1016/j.clbc.2017.06.014. Epub 2017 Jul 10.

PMID:
28755879
17.

Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation.

Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM.

Ann Surg. 2017 Jul 24. doi: 10.1097/SLA.0000000000002439. [Epub ahead of print]

PMID:
28742682
18.

Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer.

Fayanju OM, Hall CS, Bauldry JB, Karhade M, Valad LM, Kuerer HM, DeSnyder SM, Barcenas CH, Lucci A.

Am J Surg. 2017 Oct;214(4):666-671. doi: 10.1016/j.amjsurg.2017.06.005. Epub 2017 Jun 23.

19.

In response to "outcomes of patients with inflammatory breast cancer treated by breast conserving surgery": the argument against breast conservation and sentinel lymph node biopsy in IBC.

Rosso KJ, Ueno NT, Woodward WA, Lucci A.

Breast Cancer Res Treat. 2017 Oct;165(3):779-781. doi: 10.1007/s10549-017-4337-y. Epub 2017 Jul 3. No abstract available.

PMID:
28674763
20.

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.

Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A Jr, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT.

Ann Surg. 2018 May;267(5):946-951. doi: 10.1097/SLA.0000000000002313.

PMID:
28549010
21.

Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.

Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A Jr, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM.

JAMA Surg. 2017 Jul 1;152(7):665-670. doi: 10.1001/jamasurg.2017.0562.

22.

Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT.

Lancet Oncol. 2017 Apr;18(4):e228-e232. doi: 10.1016/S1470-2045(17)30192-4. Review.

PMID:
28368261
23.

Identification of frequent somatic mutations in inflammatory breast cancer.

Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT.

Breast Cancer Res Treat. 2017 Jun;163(2):263-272. doi: 10.1007/s10549-017-4165-0. Epub 2017 Feb 27.

PMID:
28243898
24.

Circulating Tumor Cells in Breast Cancer Patients.

Hall C, Valad L, Lucci A.

Crit Rev Oncog. 2016;21(1-2):125-39. doi: 10.1615/CritRevOncog.2016016120. Review.

PMID:
27481009
25.

Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction.

Carter SA, Lyons GR, Kuerer HM, Bassett RL Jr, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF.

Ann Surg Oncol. 2016 Oct;23(10):3190-8. doi: 10.1245/s10434-016-5407-9. Epub 2016 Jul 12.

PMID:
27406093
26.

Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge.

Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A.

PLoS One. 2016 Jul 8;11(7):e0159072. doi: 10.1371/journal.pone.0159072. eCollection 2016.

27.

Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients.

Hall CS, Karhade MG, Bowman Bauldry JB, Valad LM, Kuerer HM, DeSnyder SM, Lucci A.

J Am Coll Surg. 2016 Jul;223(1):20-9. doi: 10.1016/j.jamcollsurg.2016.02.021. Epub 2016 Mar 8.

28.

Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.

Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE.

J Clin Oncol. 2016 May 20;34(15):1741-7. doi: 10.1200/JCO.2015.64.1357. Epub 2016 Mar 21.

29.

Epidemiological risk factors associated with inflammatory breast cancer subtypes.

Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM.

Cancer Causes Control. 2016 Mar;27(3):359-66. doi: 10.1007/s10552-015-0712-3. Epub 2016 Jan 21.

30.

Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer.

Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, Hall C, de Groot MR, Bidard FC, Friedl TW, Fasching PA, Brucker SY, Pantel K, Lucci A.

Clin Cancer Res. 2016 May 15;22(10):2583-93. doi: 10.1158/1078-0432.CCR-15-1603. Epub 2016 Jan 5.

31.

Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer.

Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, DeSnyder S, Anderson AE, Valero V, Ueno NT, Li Y, Su X, Lucci A.

J Natl Cancer Inst. 2015 Sep 14;107(11). pii: djv250. doi: 10.1093/jnci/djv250. Print 2015 Nov.

32.

Assessment of Practice Patterns Following Publication of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer.

DeSnyder SM, Hunt KK, Smith BD, Moran MS, Klimberg S, Lucci A.

Ann Surg Oncol. 2015 Oct;22(10):3250-6. doi: 10.1245/s10434-015-4666-1. Epub 2015 Jul 23.

33.

Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT.

Breast Cancer Res Treat. 2015 Jul;152(2):417. doi: 10.1007/s10549-015-3477-1. No abstract available.

PMID:
26092296
34.

Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT.

Breast Cancer Res Treat. 2015 Jul;152(2):407-16. doi: 10.1007/s10549-015-3436-x. Epub 2015 May 29. Erratum in: Breast Cancer Res Treat. 2015 Jul;152(2):417.

35.

Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study.

Roland CL, Ross MI, Hall CS, Laubacher B, Upshaw J, Anderson AE, Lucci A.

Melanoma Res. 2015 Aug;25(4):335-41. doi: 10.1097/CMR.0000000000000168.

36.

Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.

Hall C, Karhade M, Laubacher B, Anderson A, Kuerer H, DeSynder S, Lucci A.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S552-8. doi: 10.1245/s10434-015-4600-6. Epub 2015 May 13.

PMID:
25968619
37.

Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes.

Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE.

J Invest Dermatol. 2015 Sep;135(9):2266-2272. doi: 10.1038/jid.2015.138. Epub 2015 Apr 7.

38.

Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema.

Cromwell KD, Chiang YJ, Armer J, Heppner PP, Mungovan K, Ross MI, Gershenwald JE, Lee JE, Royal RE, Lucci A, Cormier JN.

Eur J Cancer Care (Engl). 2015 Sep;24(5):724-33. doi: 10.1111/ecc.12311. Epub 2015 Mar 24.

39.

C-reactive protein as a marker of melanoma progression.

Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE.

J Clin Oncol. 2015 Apr 20;33(12):1389-96. doi: 10.1200/JCO.2014.58.0209. Epub 2015 Mar 16.

40.

Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis.

Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R.

Cancer Cell. 2014 Nov 10;26(5):707-21. doi: 10.1016/j.ccell.2014.09.005. Epub 2014 Oct 23.

41.

Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.

Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, Klimberg VS, Koczwara B, Kühn T, Lippman ME, Lucci A, Piccart M, Smith BD, Tjan-Heijnen VC, van de Velde CJ, Van Zee KJ, Vermorken JB, Viale G, Voogd AC, Wapnir IL, White JR, Smidt ML.

J Natl Cancer Inst. 2014 Nov 7;106(12). pii: dju288. doi: 10.1093/jnci/dju288. Print 2014 Dec.

42.

Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents.

Singh B, Shamsnia A, Raythatha MR, Milligan RD, Cady AM, Madan S, Lucci A.

PLoS One. 2014 Oct 3;9(10):e109487. doi: 10.1371/journal.pone.0109487. eCollection 2014.

43.

The relationship between blood IL-12p40 level and melanoma progression.

Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Sui D, Bassett RL Jr, Wang LE, Wei Q, Amos CI, Lee JE.

Int J Cancer. 2015 Apr 15;136(8):1874-80. doi: 10.1002/ijc.29182. Epub 2014 Sep 18.

44.

Circulating tumor cells in non-metastatic triple-negative breast cancer.

Karhade M, Hall C, Mishra P, Anderson A, Kuerer H, Bedrosian I, Krishnamurthy S, Lucci A.

Breast Cancer Res Treat. 2014 Sep;147(2):325-33. doi: 10.1007/s10549-014-3103-7. Epub 2014 Aug 28.

45.

Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients.

Mosalpuria K, Hall C, Krishnamurthy S, Lodhi A, Hallman DM, Baraniuk MS, Bhattacharyya A, Lucci A.

Mol Clin Oncol. 2014 Sep;2(5):845-850. Epub 2014 Jun 23.

46.

Aldehyde dehydrogenase1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with the presence of circulating or disseminated tumors cells.

Woodward WA, Krishnamurthy S, Lodhi A, Xiao L, Gong Y, Cristofanilli M, Buchholz TA, Lucci A.

J Cancer. 2014 Apr 7;5(5):360-7. doi: 10.7150/jca.7885. eCollection 2014.

47.

Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.

Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ.

Ann Oncol. 2014 Feb;25(2):358-65. doi: 10.1093/annonc/mdt496. Epub 2013 Dec 2.

48.

Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma.

Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez-Macgregor M, Alvarez R, Lucci A, Valero V, Ueno NT.

Springerplus. 2013 Aug 28;2:409. doi: 10.1186/2193-1801-2-409. eCollection 2013.

49.

Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted?

Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, Mittendorf EA, Babiera GV, Black DM, Wagner JL, Bedrosian I, Woodward W, Gainer SM, Hwang R, Meric-Bernstam F, Hunt KK, Kuerer HM.

Ann Surg Oncol. 2013 Dec;20(13):4103-12. doi: 10.1245/s10434-013-3194-0. Epub 2013 Aug 23.

50.

Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients.

Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K, Krishnamurthy S, Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Lucci A, Reuben JM.

Ann Oncol. 2013 Oct;24(10):2515-21. doi: 10.1093/annonc/mdt223. Epub 2013 Jun 24.

Supplemental Content

Support Center